Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Enzon Pharmaceuticals, Inc. ENZN OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
64/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Enzon Pharmaceuticals, Inc. (ENZN) is a Biotechnology company in the Healthcare sector, currently trading at $6.00. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 1 out of 7 criteria passed.

Net income is $3M (loss), growing at +102.8%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $0 against $42M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 58.57 (strong liquidity). Debt-to-assets is 0%. Total assets: $43M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 50/100 (Partial), Health 100/100 (Pass), Moat 46/100 (Partial), Future ?/100 (Fail), Income ?/100 (Fail).

ENZN SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENZN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
ENZN: -100%/yr revenue is, +102.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
ENZN: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet ENZN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 58.57 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
ENZN: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0477-12.99
Volume207.73K
Avg Volume (30D)718
Market Cap$4.45M
Beta (1Y)0.08
Share Statistics
EPS (TTM)-7.46
Shares Outstanding$742.15K
IPO Date1984-02-15
CEORichard L. Feinstein
Financial Highlights & Ratios
EBITDA$-1.36M
Net Income$-3.41M
Operating Income$-1.36M
Total Cash$42.57M
Net Debt$-42.57M
Total Assets$42.81M
Price / Earnings (P/E)-0.8
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS2939041081

Price Chart

Track all markets on TradingView
ENZN
Enzon Pharmaceuticals, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.05 52WK RANGE 12.99

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 NAMS
NAMS
NewAmsterdam Pharma Company N.V.
$34.01
-1.25%
 PRTC
PRTC
PureTech Health plc
$18.25
+2.13%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 MOLN
MOLN
Molecular Partners AG
$4.20
+1.45%
 PMVP
PMVP
PMV Pharmaceuticals, Inc.
$1.41
-4.08%
 ACRV
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.67
+1.83%
 LVCLF
LVCLF
Living Cell Technologies Limited
$0.01
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message